Search Results

QuVa Pharma, Inc. announced that it is expanding its RFID embedded, pre-tagged product label platform to include RFID tags that adhere to GS1’s open, technology independent, global standards which enable interoperability and compatibility.

President Trump also refused to promise pharma execs that he would hamstring the IRA’s drug negotiation program.

QuVa Pharma, Inc. announced that it is expanding its product label platform by adding 2D barcodes on all products, adhering to GS1 standards.

One of the lowest paid CEOs in pharma—and one of the only woman leading a top-tier giant—is set to receive up to $27.2 million in 2025.

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives find themselves faced with policy questions ranging from the Inflation Reduction Act to RFK Jr.

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved into a new pharma stratosphere, far eclipsing their rivals.

As FDA seeks to rehire some fired employees, Donald Trump threatens to enact tariffs on pharma companies unless they reshore manufacturing; another lawsuit hits the complex GLP-1 compounding space as Eli Lilly offers expanded Zepbound options; and struggling gene therapy biotech bluebird bio goes private in an attempt to stay solvent.

QuVa Pharma, Inc. announced that is has developed a two-sided single label for its product portfolio of compounded IV bags.

China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.